A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Public ClinicalTrials.gov record NCT06581198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Study identification
- NCT ID
- NCT06581198
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 179 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 4, 2024 (Actual)
- Primary completion
- Feb 14, 2028 (Estimated)
- Completion
- Feb 6, 2032 (Estimated)
- Last update posted
- Sep 2, 2026
2024 – 2032
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Alabama | Birmingham | Alabama | 35294 | — |
| Loma Linda University | San Bernardino | California | 92408 | — |
| UCSF | San Francisco | California | 94115 | — |
| Sutter Health Network | San Pablo | California | 94806 | — |
| Ann and Robert H Lurie Childs Hosp | Chicago | Illinois | 60611 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University Of Iowa | Iowa City | Iowa | 52242 | — |
| University of Kentucky | Lexington | Kentucky | 40536-0284 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| WA Uni School Of Med | St Louis | Missouri | 63110 | — |
| Duke Clinical Research Institute | Durham | North Carolina | 27710 | — |
| James Cancer Hospital | Columbus | Ohio | 43210 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| Univ Of TX MD Anderson CC | Houston | Texas | 77030 | — |
| LDS Hospital | Salt Lake City | Utah | 84143 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06581198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06581198 live on ClinicalTrials.gov.